The Food and Drug Administration on Thursday approved a higher dose of Novo Nordisk’s Wegovy, a leading medication for weight loss, as the Danish pharmaceutical company aims to regain ground in a rapidly evolving market. The approval of the 7.2-milligram dose of Wegovy comes as Novo Nordisk faces increasing competition from Eli Lilly’s Zepbound, which has demonstrated greater efficacy in clinical trials. This move underscores the intensifying race to address the growing global obesity epidemic and the demand for effective treatment options.
The higher-dose Wegovy is slated for launch in April, according to Novo Nordisk. Clinical trials showed that patients receiving the 7.2-milligram dose experienced an average weight loss of 20.7% over 72 weeks, a significant increase compared to the approximately 15% weight loss observed with the standard 2.4-milligram dose. This enhanced efficacy is a direct response to the success of Zepbound, which has quickly become a preferred choice among both physicians and patients seeking substantial weight reduction.
Competition Heats Up in the Obesity Drug Market
Zepbound’s strong performance has solidified Eli Lilly’s position as a dominant player in the obesity treatment space, despite entering the market later than Wegovy. The increased efficacy of Zepbound has resonated with prescribers and patients alike, driving its adoption and market share. Novo Nordisk’s decision to introduce a higher dose of Wegovy is a strategic effort to close this gap and offer a more competitive option for individuals struggling with obesity.
“I think it really makes it more competitive, and it really reduces the delta there,” said Dr. Jason Brett, principal U.S. Medical head at Novo Nordisk, in an interview ahead of the FDA approval. “But even more importantly, I think it just gives patients another option if they’re not reaching their targets, and achieving some of these higher weight losses for certain patients.”
Efficacy Across Different Patient Groups
The benefits of the higher-dose Wegovy extend beyond individuals with uncomplicated obesity. A separate phase three trial demonstrated an average weight loss of 14.1% in patients with both obesity and Type 2 diabetes. Here’s particularly significant, as individuals with diabetes often face greater challenges in achieving weight loss compared to those without the condition. The results suggest that the higher dose may be particularly beneficial for this patient population.
Speedy-Tracked Approval Under New FDA Program
The FDA’s approval of the higher-dose Wegovy as well marks a milestone as the first GLP-1 treatment to be approved under the agency’s new national priority voucher plan. Launched in June, this program aims to expedite the review process for drugs addressing critical national health priorities, potentially reducing review times to just one to two months. The initiative reflects the FDA’s commitment to accelerating the availability of innovative treatments for pressing public health concerns.
Impact of Hims & Hers Copycat Pill
Novo Nordisk has also been navigating challenges related to a cheaper copycat version of Wegovy offered by telehealth provider Hims & Hers. In February 2026, Hims announced it would sell a compounded version of the Wegovy pill for $49, significantly lower than Novo Nordisk’s price of $149. Novo Nordisk responded by stating it would take legal action, arguing that Hims & Hers’ actions constitute illegal mass compounding and pose a risk to patient safety. Shares of both Novo Nordisk and Eli Lilly experienced a decline following the announcement, highlighting the market’s sensitivity to pricing and competition in the weight loss drug sector.
The introduction of the higher-dose Wegovy is a pivotal moment in the ongoing evolution of obesity treatment. As the market continues to expand and new players emerge, the focus remains on providing effective and accessible solutions for individuals seeking to manage their weight and improve their overall health. The FDA’s expedited review process and the competitive dynamics between Novo Nordisk and Eli Lilly are shaping the future of this critical area of healthcare.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next key date to watch is April, when Novo Nordisk expects to launch the higher-dose Wegovy. Further updates on market share, patient outcomes, and potential legal developments regarding the Hims & Hers copycat pill will also be closely monitored. Share your thoughts on this evolving landscape in the comments below.
